FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

Phase 2

Completed

Conditions: Recurrent Bladder Urothelial Carcinoma
Stage 0is Bladder Cancer AJCC v8
Bladder Urothelial Carcinoma In Situ
Stage 0a Bladder Cancer AJCC v8
Stage I Bladder Cancer AJCC v8
Superficial Bladder Urothelial Carcinoma

Interventions: Device: Acupuncture Therapy
Biological: BCG Solution
Other: Best Practice
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2020-08-03

Last Posted Date: 2024-01-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 45

Registration Number: NCT04496219

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

Phase 1

Withdrawn

Conditions: Plasma Cell Myeloma

Interventions: Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation

First Posted Date: 2020-07-10

Last Posted Date: 2024-01-31

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT04466475

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Telephone Delivered Weight Loss, Nutrition, Exercise WeLNES Study

Phase 3

Active, not recruiting

Conditions: Obesity-Related Malignant Neoplasm

Interventions: Other: Survey Administration
Behavioral: Telephone-Based Intervention

First Posted Date: 2020-06-25

Last Posted Date: 2024-08-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 418

Registration Number: NCT04447313

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Cancer Communication Within Hispanic Social Networks

Not Applicable

Completed

Conditions: Colorectal Carcinoma

Interventions: Other: Media Intervention
Other: Survey Administration

First Posted Date: 2020-06-23

Last Posted Date: 2020-06-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 57

Registration Number: NCT04444232

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

Recruiting

Conditions: Chronic Graft Versus Host Disease

Interventions: Procedure: Biospecimen Collection
Other: Medical Chart Review
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2020-06-16

Last Posted Date: 2024-03-26

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 200

Registration Number: NCT04431479

Locations: 🇺🇸
Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 7 locations

Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking

Phase 3

Active, not recruiting

Conditions: Malignant Solid Neoplasm
Hematopoietic and Lymphoid System Neoplasm

Interventions: Behavioral: Quit2Heal
Behavioral: QuitGuide
Other: Survey Administration

First Posted Date: 2020-06-01

Last Posted Date: 2024-07-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 427

Registration Number: NCT04409236

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Vaccine Responsiveness After CAR-T Cell Therapy

Phase 1

Recruiting

Conditions: B-Cell Neoplasm

Interventions: Biological: Wistar Rabies Virus Strain PM-1503-3M Vaccine
Procedure: Biospecimen Collection

First Posted Date: 2020-06-01

Last Posted Date: 2024-03-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 43

Registration Number: NCT04410900

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

Phase 2

Recruiting

Conditions: Secondary Myelofibrosis
Primary Myelofibrosis

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Melphalan
Drug: Methotrexate
Drug: Mycophenolate Mofetil
Drug: Ruxolitinib
Drug: Tacrolimus
Radiation: Total-Body Irradiation
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Magnetic Resonance Imaging
Procedure: Ultrasound Imaging

First Posted Date: 2020-05-12

Last Posted Date: 2024-10-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 45

Registration Number: NCT04384692

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Phase 1

Recruiting

Conditions: Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory Chronic Myelomonocytic Leukemia
Refractory Mixed Phenotype Acute Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome
Refractory Acute Leukemia of Ambiguous Lineage
Refractory Acute Undifferentiated Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cladribine
Drug: Cyclosporine
Drug: Cytarabine
Biological: Filgrastim
Procedure: Hematopoietic Cell Transplantation
Drug: Mitoxantrone
Drug: Idarubicin
Drug: Mycophenolate Mofetil
Drug: Fludarabine
Drug: Mycophenolate Sodium
Radiation: Total-Body Irradiation
Procedure: Multigated Acquisition Scan
Procedure: Echocardiography
Procedure: X-Ray Imaging
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection

First Posted Date: 2020-05-05

Last Posted Date: 2024-11-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 120

Registration Number: NCT04375631

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Phase 2

Recruiting

Conditions: Primary Myelofibrosis
Secondary Myelofibrosis

Interventions: Drug: Cyclophosphamide
Drug: JAK Inhibitor
Drug: Fludarabine
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Tacrolimus
Radiation: Total-Body Irradiation
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan

First Posted Date: 2020-04-30

Last Posted Date: 2024-07-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT04370301

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy